Q Biomed Inc.

42 articles with Q Biomed Inc.

• 

  BioSpace Movers and Shakers Sept. 24

  9/24/2018

  Here's a look at who's making moves in the biotech and pharma world this week.

• Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board

  9/17/2018

  Distinguished Ophthalmology Specialist Brings Wealth of Experience

• Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain

  8/20/2018

  Prior Approval Supplement Filing Under GDUFA Guidelines is Final Step in Approval Process

• Q Biomed Inc. Extends its Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma and Initiates a Clinical Study

  7/25/2018

  Q BioMed Inc. is pleased to announce that it is extending its option agreement with Washington University in St. Louis.

• 

  Increased Development of Non-Opioid Pain Treatments is Expected to Continue

  6/29/2018

  With increased worries over the addictive nature of opioid-based pain treatments, more and more companies are focusing on the development of effective treatments without the addictive nature.

• Q BioMed Inc. Provides Important Update on Mannin Research Tie2 Technology Platform Development

  6/6/2018

  Together with Mannin Research, the company has made significant progress on their Tie2 activating molecule

• Q BioMed Inc Places 2nd in Company Category for Autism Speaks Walk Fundraiser

  6/1/2018

  Company makes effort to connect with patients and caregivers as it progress its potential treatment for an Autistic Spectrum Nonverbal Developmental Disorder

• Q Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing Facility for Non-Opioid Strontium Chloride SR89 Injection USP for Relief of Cancer Bone Pain

  3/16/2018

  Q Biomed Inc.  (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, and Bio-Nucleonics, licensor of Strontium 89 Chloride, announce submission of a regulatory filing to the FDA for the approval of a new manufacturing facility.

• Q BioMed Adds Big Pharma Executive to Board of Directors

  2/13/2018

  Q Biomed is pleased to welcome Dr. Rick Panicucci as an independent member on its board of Directors.

• Q Biomed Signs Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma

  2/8/2018

  Q Biomed is pleased to announce an exclusive option agreement with Washington University in St. Louis.

• Q BioMed Prices $5.5M Public Offering

  1/30/2018

  Q Biomed is pleased to announce pricing of a public offering of an aggregate of 1,711,875 shares of common stock of the Company.

• Q BioMed Inc. Provides Year End Update

  12/22/2017

  Q Biomed is pleased to provide this year end update to its shareholders.

• Q BioMed Announces Full Settlement of All Convertible Debt

  12/5/2017

  Q Biomed announced today that all convertible notes and loans have been settled in full, including the $4M of convertible notes that had been issued pursuant to a Securities Purchase Agreement dated November 29, 2016.

• Q BioMed Adds Boston University's Dr. Tager-Flusberg to Advisory Committee

  11/28/2017

  Q Biomed announced today that Dr. Helen Tager-Flusberg from Boston University has joined its advisory committee for QBM-001, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders.

• Q Biomed Announces Funding to Technology Partner Mannin Research to Expand Product Pipeline

  11/14/2017

  Q Biomed congratulates our collaborative research partner and licensor, Mannin Research, on receiving R&D funding from the NRC IRAP to initiate work on a Tie2-activating biologic for the treatment of glaucoma.

• Q BioMed Announces Identification and Production of New Proprietary Drug Candidate for Pediatric Nonverbal Disorder

  10/19/2017

  Q BioMed today that it has successfully developed a new and proprietary analog of QBM-001 in partnership with Sphaera Pharma for its intended use in pediatric developmental nonverbal disorder.

• Q Biomed Announces Favorable Amendment To Debenture Financing

  10/12/2017

• Q Biomed Announces Launch Of PainFreeCancer.com Website In Support Of Non-Opioid Cancer Pain Drug

  10/6/2017

• Q Biomed Announces Development Partnership With Sphaera Pharma

  9/19/2017

• Q Biomed Adds Nuclear Medicine Industry Veteran To Commercialization Team

  6/27/2017